Simplifying Global Compliance
Biogen to Acquire Biotech Firm
Biogen Idec said it will pay $75 million upfront and as much as $487.5 million in future payments to acquire closely held biotechnology company Stromedix, which is working on a treatment for damaging scar tissue in the lungs and other organs.
The Wall Street Journal
Copyright ©2014. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing